Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05057247 · ClinicalTrials.gov registry record · Phase 2
Duvelisib Plus Docetaxel In Recurrent/Metastatic HNSCC
A Phase 2 study of Advanced Head and Neck Squamous Cell Carcinoma and Metastatic Head and Neck Cancer, sponsored by Glenn J. Hanna.
- Completed
- Registry status
- Phase 2
- Development phase
- 26
- Enrollment target
- 1
- Study location
NCT05057247 is a Phase 2 study of Advanced Head and Neck Squamous Cell Carcinoma and Metastatic Head and Neck Cancer that has completed, run by Glenn J. Hanna. The registered enrollment target is 26 participants, below the 35-participant average among 5 other Advanced Head and Neck Squamous Cell Carcinoma trials with a reported enrollment target (26% lower). The trial reports 1 study location across 1 state.
The verdict
NCT05057247, a Phase 2 study of Advanced Head and Neck Squamous Cell Carcinoma and Metastatic Head and Neck Cancer, has completed, sponsored by Glenn J. Hanna.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 26 participants
- Enrollment target
- 1
- Study location
Study Summary
This trial that is investigating a medication called duvelisib in combination with docetaxel for the treatment of squamous cell carcinoma of the head and neck (SCCHN) that has returned or spread outside the head and neck area. The names of the study drugs involved in this study are: * Duvelisib (PI3K inhibitor) * Docetaxel chemotherapy
Conditions Studied
Interventions
- DRUG Docetaxel
- DRUG Duvelisib
Study Locations (1)
Massachusetts
- Dana Farber Cancer Institute - Boston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 26 participants |
| Start Date | 2021-10-14 |
| Est. Completion | 2024-06-13 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05057247
The ClinicalTrials.gov registry entry for NCT05057247 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 26 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 35-participant average among 5 other Advanced Head and Neck Squamous Cell Carcinoma trials with a reported enrollment target (26% lower). The listed sponsor is Glenn J. Hanna, which has 7 total studies on file at ClinicalTrials.gov.
The record links to 5 conditions, with Advanced Head and Neck Squamous Cell Carcinoma appearing as the primary indexed condition, and to 2 interventions - of which Docetaxel is the first listed.
NCT05057247 reports 1 study location spanning 1 distinct geographic area - top geographies include Massachusetts.
Frequently Asked Questions
What is clinical trial NCT05057247 about?
NCT05057247 is a clinical study titled "Duvelisib Plus Docetaxel In Recurrent/Metastatic HNSCC". This trial that is investigating a medication called duvelisib in combination with docetaxel for the treatment of squamous cell carcinoma of the head and neck (SCCHN) that has returned or spread outside the head and neck area. The names of the study drugs involved in this study are: * Duvelisib (P...
What is the current status of trial NCT05057247?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 26 participants. The study started on 2021-10-14. Estimated completion is 2024-06-13.
What conditions does trial NCT05057247 study?
This clinical trial studies the following conditions: Advanced Head and Neck Squamous Cell Carcinoma, Metastatic Head and Neck Cancer, Squamous Cell Carcinoma of the Head and Neck (SCCHN), Recurrent Squamous Cell Carcinoma of the Head and Neck, Advanced Head and Neck Cancer.
What interventions are being tested in trial NCT05057247?
The interventions under investigation include: Docetaxel (DRUG), Duvelisib (DRUG).
Who is sponsoring clinical trial NCT05057247?
This trial is sponsored by Glenn J. Hanna, which has 7 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05057247 being conducted?
This trial has 1 study location across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Advanced Head and Neck Squamous Cell Carcinoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Ivonescimab Before Surgery for the Treatment of Resectable Stage II-IV Head and Neck Cancer
RECRUITING · Phase 2
-
Quad Shot Radiotherapy in Combination With Immune Checkpoint Inhibition
COMPLETED · Phase 2
-
IACS-6274 With or Without Bevacizumab and Paclitaxel for the Treatment of Advanced Solid Tumors
RECRUITING · Phase 1
-
CIMAvax Vaccine, Nivolumab, and Pembrolizumab in Treating Patients With Advanced Non-small Cell Lung Cancer or Squamous Head and Neck Cancer
ACTIVE NOT RECRUITING · Phase 1
-
Testing the Addition of M3814 (Peposertib) to Radiation Therapy for Patients With Advanced Head and Neck Cancer Who Cannot Take Cisplatin
ACTIVE NOT RECRUITING · Phase 1
Explore more on PlainTrial
Advanced Head and Neck Squamous Cell Carcinoma
All registered trials for this condition
Metastatic Head and Neck Cancer
All registered trials for this condition
Massachusetts
All trials with a study site in Massachusetts
Recruiting now
Find trials open to new participants near you
Rankings
Top sponsors, conditions, and phases
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.